title: Induction of colitis in cftr-/- mice results in bile duct injury.
abstract: It is unknown why some patients with inflammatory bowel disease develop primary sclerosing cholangitis. We have recently shown that patients with primary sclerosing cholangitis have an increased prevalence of mutations in the gene responsible for cystic fibrosis (CFTR) compared with individuals with inflammatory bowel disease alone. Our aim was to examine whether induction of colitis by oral dextran leads to bile duct injury in mice heterozygous or homozygous for mutations in CFTR. The effect of oral administration of docosahexaenoic acid to correct a fatty acid imbalance associated with cystic fibrosis was also examined to determine whether this would prevent bile duct inflammation. Wild-type mice and mice heterozygous and homozygous for CFTR mutations were given dextran orally for 14 days to induce colitis. Bile duct injury was quantitated by blinded histological scoring and measurement of serum alkaline phosphatase activity. The effect of pretreatment with docosahexaenoic acid for 7 days was examined. Treatment of mice with 100 mg dextran/day for 9 days followed by 85 mg/day for 5 days resulted in a significant increase in bile duct injury as determined by histological scoring in homozygous cystic fibrosis mice compared with wild-type mice (P = 0.005). The bile duct injury seen in cystic fibrosis mice was reflected in a threefold increase in serum alkaline phosphatase (P = 0.0006). Pretreatment with oral docosahexaenoic acid decreased both histological evidence of bile duct injury and serum alkaline phosphatase levels. In the setting of colitis, loss of CFTR function leads to bile duct injury.
authors.affiliation: Beth Israel Deaconess Medical Center, 330 Brookline Ave., Dana 501, Boston, MA 02215, USA.
authors.forename: Paola G
authors.initials: PG
authors.lastname: Blanco
authors.forename: Munir M
authors.initials: MM
authors.lastname: Zaman
authors.forename: Omer
authors.initials: O
authors.lastname: Junaidi
authors.forename: Sunil
authors.initials: S
authors.lastname: Sheth
authors.forename: Rhonda K
authors.initials: RK
authors.lastname: Yantiss
authors.forename: Imad A
authors.initials: IA
authors.lastname: Nasser
authors.forename: Steven D
authors.initials: SD
authors.lastname: Freedman
mesh_terms: D000284:Administration, Oral; D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D001652:Bile Ducts / Q000187:drug effects / Q000473:pathology*; D003092:Colitis / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology*; D003106:Colon / Q000473:pathology; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000172:deficiency* / Q000235:genetics; D016264:Dextran Sulfate / Q000008:administration & dosage; D004281:Docosahexaenoic Acids / Q000008:administration & dosage; D006579:Heterozygote; D006720:Homozygote; D051379:Mice; D018345:Mice, Knockout; D009154:Mutation
chemical_list: D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D004281:Docosahexaenoic Acids; D016264:Dextran Sulfate; D000469:Alkaline Phosphatase